GlennJHannaMD

Head & Neck Cancer, Hematologic Oncology

Assistant Professor of Medicine, Dana-Farber Cancer Institute

Dr. Hanna is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-3090

Fax+1 617-632-4448

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2014 - 2016
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2011 - 2014
Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolInternship, Otolaryngology - Head and Neck Surgery, 2010 - 2011
Georgetown University School of MedicineClass of 2010

Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia Start of enrollment: 2018 Dec 05
Active, not recruiting
Phase 2
A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma Start of enrollment: 2019 Aug 05
Completed
Phase 2
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas Start of enrollment: 2020 Dec 24
Recruiting
Phase 2
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma Start of enrollment: 2030 Dec 18
Withdrawn
Phase 2
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial Start of enrollment: 2021 Dec 27
Recruiting
Not Applicable
Cemiplimab in AlloSCT/SOT Recipients With CSCC Start of enrollment: 2020 Nov 03
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
CIML NK Cell in Head & Neck Cancer Start of enrollment: 2020 Jul 20
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Drug Screening Using Novel IMD in ACC and Salivary Cancers Start of enrollment: 2023 Nov 01
Not yet recruiting
Early Phase 1
Roles: Contact, Principal Investigator
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC Start of enrollment: 2023 Jun 01
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Sponsor-Investigator, Contact
Join now to see all

PubMed

46 citations
Detection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among Patients Treated for HPV-Driven Oropharyngeal Carcinoma.
Barry M Berger, Glenn J Hanna, Marshall R Posner, Eric M Genden, Julio Lautersztain
Clinical Cancer Research. 2022-10-03
13 citations
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.
Glenn J Hanna, Harita Dharanesswaran, Anita Giobbie-Hurder, John J Harran, Zixi Liao
Journal of Clinical Oncology. 2024-03-20
97 citations
A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant
Naoka Murakami, Patrick M. Mulvaney, Melissa J. Danesh, Ala Abudayyeh, Adi Diab
Kidney International. 2021-07-01

Journal Articles

Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma
Glenn J Hanna, Nicole Chau, Jochen Lorch, Robert I Haddad, JAMA Oncology
Genomic Correlates of Response to Immune Checkpoint Blockade in Microsatellite-Stable Solid Tumors
Jeffrey A Engelman, David A Barbie, Nicole G Chau, Glenn J Hanna, Natalie I Vokes, Sabina Signoretti, Pasi A Janne, Robert I Haddad, Lynette M Sholl, Rizwan Haq, Peter..., Nature
CIC‐NUTM1 Fusion: A Case Which Expands the Spectrum of NUT‐Rearranged Epithelioid Malignancies
Glenn J Hanna, Christopher A French, Genes, Chromosomes and Cancer

Lectures

An open label, multicenter, phase II study of KRT-232, an oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel cell carcinoma (MCC) who hav...
2019 ASCO Annual Meeting - 6/1/2019

Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell CarcinomaAugust 2020

Higher Cancer Risk with Heavy Cannabis Use – US StudyAugust 21st, 2024
Heavy Cannabis Use May Increase Risk of Certain Cancers, New Study FindsAugust 8th, 2024
New Open Access Journal, Cancer Research Communications, Expands the Reach of the AACR JournalsJanuary 11th, 2022
Join now to see all